OVID stock continues to move higher for the fourth straight session and jumps another 10% this morning after Ovid Therapeutics’ (NASDAQ:OVID) product “OV101” won orphan drug designation by the European Commission.
Another Key AnnouncementOvid Therapeutics, which is based out of New York, has been one of the bigger gainers in the biopharmaceutical space over the past week, and today, the company received significantly positive news again. In a new development, the company’s product OV101 has been awarded the coveted orphan drug designation by the European Commission, and it goes without saying that it is an ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.